Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

The article reports that a multi-site clinical study produced strong performance data for an Intelligent Fingerprinting Drug Screening System. No quantitative outcomes (e.g., sensitivity/specificity, sample size) or commercial/financial impacts are provided, limiting visibility into magnitude for investors.